Open AccessFab-based inhibitors reveal ubiquitin independent functions for HIV Vif neutralization of APOBEC3 restriction factors
Author(s) -
Jennifer M. Binning,
Amber M. Smith,
Judd F. Hultquist,
Charles S. Craik,
Nathalie Caretta Cartozo,
Melody G. Campbell,
Lily Burton,
Florencia La Greca,
Michael McGregor,
Hai Minh Ta,
Koen Bartholomeeusen,
B. Matija Peterlin,
Nevan J. Krogan,
Natalia Sevillano,
Yifan Cheng,
John D. Gross
Publication year - 2018
Publication title -
plos pathogens
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.719
H-Index - 206
eISSN - 1553-7374
pISSN - 1553-7366
DOI - 10.1371/journal.ppat.1006830
Subject(s) - ubiquitin , ubiquitin ligase , microbiology and biotechnology , biology , innate immune system , neutralization , infectivity , apobec3g , virology , viral replication , virus , chemistry , immune system , biochemistry , genetics , gene
The lentiviral protein Viral Infectivity Factor (Vif) counteracts the antiviral effects of host APOBEC3 (A3) proteins and contributes to persistent HIV infection. Vif targets A3 restriction factors for ubiquitination and proteasomal degradation by recruiting them to a multi-protein ubiquitin E3 ligase complex. Here, we describe a degradation-independent mechanism of Vif-mediated antagonism that was revealed through detailed structure-function studies of antibody antigen-binding fragments (Fabs) to the Vif complex. Two Fabs were found to inhibit Vif-mediated A3 neutralization through distinct mechanisms: shielding A3 from ubiquitin transfer and blocking Vif E3 assembly. Combined biochemical, cell biological and structural studies reveal that disruption of Vif E3 assembly inhibited A3 ubiquitination but was not sufficient to restore its packaging into viral particles and antiviral activity. These observations establish that Vif can neutralize A3 family members in a degradation-independent manner. Additionally, this work highlights the potential of Fabs as functional probes, and illuminates how Vif uses a multi-pronged approach involving both degradation dependent and independent mechanisms to suppress A3 innate immunity.